22
Participants
Start Date
August 31, 2015
Primary Completion Date
August 31, 2018
Study Completion Date
August 31, 2023
bendamustine, rituximab
subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
RECRUITING
Asan Medical Center, Seoul
Lead Sponsor
Cheolwon Suh
UNKNOWN
Asan Medical Center
OTHER